Polypoidal choroidal vasculopathy in Korean patients with large submacular hemorrhage

Yonsei Med J. 2007 Apr 30;48(2):225-32. doi: 10.3349/ymj.2007.48.2.225.

Abstract

Purpose: To determine and compare the clinical characteristics, visual prognosis and treatment of hemorrhagic polypoidal choroidal vasculopathy (HPCV) with those of hemorrhagic choroidal neovascularization (HCNV) due to age-related macular degeneration (ARMD).

Materials and methods: Retrospective analysis of 44 consecutive eyes with a submacular hemorrhage comprising more than 50% of the neovascular lesion. Patients were diagnosed as having HPCV or HCNV on the basis of indocyanine green angiography.

Results: Of the 44 eyes with submacular hemorrhage, 26 were classified as HPCV and 18 as HCNV. The baseline patient characteristics were similar for both groups. At the final follow-up the HPCV group had 17 eyes showing visual improvement, four showing maintained vision, and five showing visual deterioration. In contrast, the HCNV group had four eyes showing visual improvement, one showing maintained vision, and 13 showing visual deterioration. Visual acuity of < 0.1 at follow-up was found in 7 (27%) of HPCV eyes and 10 (56%) of HCNV eyes. PDT was performed in 15 HPCV eyes, of which 13 (87%) showed improvement or no change in visual acuity, while only 2 (22%) of the 9 HCNV eyes responded similarly after PDT. Eyes treated with PDT did not have better outcomes compared to eyes that underwent other types of treatment (Fisher's exact test, p > 0.05).

Conclusion: PCV accounts for the largest proportion of submacular hemorrhage in Koreans. PCV showed a better visual prognosis than CNV.

MeSH terms

  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / epidemiology*
  • Female
  • Follow-Up Studies
  • Humans
  • Korea / epidemiology
  • Macular Degeneration / drug therapy
  • Macular Degeneration / epidemiology
  • Male
  • Middle Aged
  • Photochemotherapy
  • Retinal Hemorrhage / drug therapy
  • Retinal Hemorrhage / epidemiology*
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome
  • Vision Disorders / etiology

Substances

  • Tissue Plasminogen Activator